Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021736 · ClinicalTrials.gov registry record · Phase 2
Phase II/III Study of Anti-VEGF in Neovascular AMD
A Phase 2 study, sponsored by Eyetech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 540
- Enrollment target
NCT00021736: Completed Phase 2 study, sponsored by Eyetech Pharmaceuticals.
NCT00021736 is a Phase 2 study that has completed, run by Eyetech Pharmaceuticals. The registered enrollment target is 540 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (306% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021736, a Phase 2 study, has completed, sponsored by Eyetech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 540 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
Interventions
- DRUG EYE001 anti-VEGF aptamer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2001-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 2 |
What the finished NCT00021736 record still lists
NCT00021736 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (306% higher).
The record links to 0 conditions, and to 1 intervention - of which EYE001 anti-VEGF aptamer is the first listed.
NCT00021736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021736 about?
NCT00021736 is a clinical study titled "Phase II/III Study of Anti-VEGF in Neovascular AMD". The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
What is the current status of trial NCT00021736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 540 participants. The study started on 2001-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00021736?
The interventions under investigation include: EYE001 anti-VEGF aptamer (DRUG).
Who is sponsoring clinical trial NCT00021736?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00021736's enrollment target sits among peer trials
540 62nd of 2000 higher than 1,938 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia